🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. -, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -

    Pharma Mar S.A.

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  2. -, Rozanolixizumab

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. -, Rozanolixizumab

    Pharma Mar S.A.

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis

    Pharma Mar S.A.

    Alzheimer's Disease Psychosis

    phase 3 other active

    1 trial

  5. A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

    Pharma Mar S.A.

    Lewy body Dementia psychosis (LBDP)

    phase 3 other active

    1 trial

  6. ABIRATERONE, 177Lu-PNT2002, GALLIUM (68GA) GOZETOTIDE , ENZALUTAMIDE

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  7. ABO-102, ABO-102, ABO-102

    Pharma Mar S.A.

    Mucopolysaccharidosis type IIIA

    phase 3 small molecule active

    1 trial

  8. AMX0035, PL1 Oral powder in sachet, oral use

    Pharma Mar S.A.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule active

    1 trial

  9. APL-2

    Pharma Mar S.A.

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  10. ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión

    Pharma Mar S.A.

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  11. AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE

    Pharma Mar S.A.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  12. Abemaciclib, Lasofoxifene, Fulvestrant

    Pharma Mar S.A.

    Locally advanced or metastatic breast cancer

    phase 3 small molecule active

    1 trial

  13. Amisulpride, DEXAMETHASONE PHOSPHATE, ONDANSETRON

    Pharma Mar S.A.

    post-operative nausea and vomiting in pediatric patients

    phase 3 small molecule active

    1 trial

  14. An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

    Pharma Mar S.A.

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  15. Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση

    Pharma Mar S.A.

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    phase 3 small molecule active

    1 trial

  16. Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ, 50 IU/ml, prášek a rozpouštědlo pro infuzní roztok, Atenativ 500 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 50 i.e./ml prašek in vehikel za raztopino za infundiranje, Atenativ 50 IU/ml prášek a rozpouštědlo pro infuzní roztok, ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, ATENATIV 50 UI/mL, poudre et solvant pour solution p

    Pharma Mar S.A.

    Acquired Antithrombin Deficiency (Heparin Resistance)

    phase 3 small molecule active

    1 trial

  17. Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet

    Pharma Mar S.A.

    Classic Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    1 trial

  18. Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet

    Pharma Mar S.A.

    Classic congenital adrenal hyperplasia

    phase 3 small molecule active

    1 trial

  19. Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE

    Pharma Mar S.A.

    Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  20. BRUKINSA 80 mg hard capsules, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, IMBRUVICA 140 mg hard capsules, Lisaftoclax, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules, Calquence 100 mg hard capsules

    Pharma Mar S.A.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  21. Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides

    Pharma Mar S.A.

    Allergic rhinoconjunctivitis due to exposure of house dust mites

    phase 3 small molecule active

    1 trial

  22. Berotralstat, Orladeyo 150 mg hard capsules, Berotralstat, Berotralstat, Berotralstat

    Pharma Mar S.A.

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  23. Betahistine dihydrochloride, BETASERC 24 mg, comprimé

    Pharma Mar S.A.

    Menière's disease

    phase 3 small molecule active

    1 trial

  24. Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution

    Pharma Mar S.A.

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources